Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care (NASDAQ: TNDM) has announced compatibility between its t:slim X2 insulin pump with Control-IQ+ technology and Abbott's FreeStyle Libre 3 Plus sensor in the US. The integration enables automatic glucose readings every minute directly to the pump, with a 15-day sensor wear time. The Control-IQ+ technology adjusts insulin every 5 minutes based on predicted glucose values and features the unique AutoBolus feature for missed meal corrections. The company has launched an early access program and plans to expand availability in the second half of 2025. This integration aligns with American Diabetes Association recommendations for automated insulin delivery systems as the preferred method for type 1 and insulin-deficient diabetes management. The company plans to extend this compatibility to international markets later in the year.

Tandem Diabetes Care (NASDAQ: TNDM) has announced a strategic partnership with Abbott to develop and commercialize integrated diabetes management solutions. The collaboration will combine Abbott's upcoming dual glucose-ketone sensor with Tandem's insulin delivery systems. The innovative sensor under development will feature both glucose and ketone sensing capabilities, aimed at early detection of ketone rise to prevent diabetic ketoacidosis, a life-threatening condition. This integration represents a significant advancement in diabetes care technology, potentially enabling patients to make faster and more informed decisions about their health management.

Tandem Diabetes Care (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has announced its participation in three major upcoming investor conferences in May and June 2025:

• RBC Capital Markets Global Healthcare Conference on May 20, 2025 at 10:00am ET
• Jefferies Global Healthcare Conference on June 4, 2025 at 3:45pm ET
• Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025 at 8:40am ET

Management will present company updates at each conference. All presentations will be available via live webcast and archived for 30 days on Tandem's Investor Center website.

Tandem Diabetes Care reported strong Q1 2025 financial results, with worldwide sales growing 22% to $234.4 million. The company achieved record first-quarter performance, with U.S. pump sales increasing 19% and significant international growth.

Key highlights include:

• Worldwide pump shipments exceeded 28,000 units
• International sales reached $83.8 million
• U.S. sales showed robust growth with over 17,000 pump shipments
• 5-point improvement in adjusted EBITDA margin
• 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi

The company reaffirmed its 2025 guidance, projecting full-year sales between $997 million to $1.007 billion. Despite posting a GAAP net loss of $130.6 million, Tandem's non-GAAP metrics showed operational improvements, with gross margin reaching 51% compared to 49% in the previous year.

Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close.

The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss Q1 2025 financial and operating results. Investors can access the live webcast through Tandem's Investor Center website, and a recording will be available for 30 days afterward.

Tandem Diabetes Care (TNDM) announced positive results from its pivotal trial of Control-IQ+ automated insulin delivery technology for type 2 diabetes, published in The New England Journal of Medicine. The 13-week study showed significant improvements in glycemic control across a diverse population of 319 participants.

Key findings include:

• A1C reduction of 0.9% in Control-IQ+ group vs 0.3% in control group
• 2.3% A1C reduction in participants with baseline A1C ≥9%
• Time in range improved by 16%, adding 3.8 more hours/day in target range
• Insulin use decreased by 8 units/day in Control-IQ+ group

The study demonstrated effectiveness across diverse demographics, with 39% of participants from minority backgrounds. The technology proved safe with no new safety concerns, and received high usability scores regardless of participants' bolusing strategy.

Tandem Diabetes Care (NASDAQ: TNDM) has launched Control-IQ+ technology in the United States, an enhanced automated insulin delivery (AID) system now available for people with type 1 diabetes aged 2 years and older and adults with type 2 diabetes.

The new generation algorithm, compatible with both t:slim X2 insulin pump and Tandem Mobi System, offers expanded features including:

• Wider weight (20-440 lbs) and total daily insulin (5-200 units) parameters
• Enhanced extended bolus up to 8 hours with active Control-IQ+
• New Temp Basal Rate adjustments during active Control-IQ+

The technology is now shipping in pre-loaded pumps to new customers, while eligible in-warranty Tandem customers can access the update via free remote software update. The system maintains the company's unique AutoBolus™ feature, adjusting insulin every 5 minutes based on predicted glucose values.

Tandem Diabetes Care (TNDM) reported strong financial results for Q4 and full year 2024. Q4 worldwide GAAP sales grew 44% to $282.6M, with non-GAAP sales up 21% to $252.4M. Pump shipments increased by over 25% worldwide.

For full year 2024, worldwide GAAP sales rose 26% to $940.2M. The company achieved positive free cash flow and increased Tandem Mobi pump shipments throughout the year. Strategic highlights include FDA clearance for Control-IQ+ for type 2 diabetes and a multi-year collaboration with University of Virginia for closed-loop insulin delivery systems.

Looking ahead to 2025, TNDM projects full-year sales of $997M-$1.007B, with U.S. sales of $725M-$730M and international sales of $272M-$277M. Q1 2025 sales are estimated at $219M-$224M. The company expects a gross margin of approximately 54% for 2025.

Tandem Diabetes Care (Nasdaq: TNDM) has received FDA clearance for its Control-IQ+ automated insulin delivery technology for people with type 2 diabetes aged 18 and older. This next-generation algorithm, already approved for type 1 diabetes, includes enhancements to accommodate expanded weight and total daily insulin ranges.

The technology will be available for U.S. customers in March 2025. Control-IQ+ powers both the t:slim X2 and Tandem Mobi insulin delivery systems, which have shown significant clinical benefits in type 1 diabetes patients, including improved time in range and better sleep according to studies published in the New England Journal of Medicine.

The expanded indication is based on a pivotal trial involving over 300 people with type 2 diabetes, comparing the t:slim X2 pump with Control-IQ+ technology against multiple daily injections. Full study results will be presented at the International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam in March 2025.